Form 4: Sana Biotechnology Director Hans Bishop Granted 80,000 Stock Options

Sana Biotechnology, Inc. Director Hans Edgar Bishop was granted 80,000 stock options with an exercise price of $2.55, aligning his interests with long-term shareholder value.

Summary

• Hans Edgar Bishop, a Director of Sana Biotechnology, Inc. (SANA), was granted 80,000 stock options.
• The transaction date for this grant was June 5, 2025.
• The exercise price for these stock options is $2.55 per share.
• The options will vest and become exercisable as to 100% of the underlying shares on the earlier of June 5, 2026, or immediately prior to the 2026 annual meeting of stockholders of Sana Biotechnology, Inc., contingent on continuous service.
• The expiration date for these stock options is June 4, 2035.
• Following this transaction, Hans Edgar Bishop beneficially owns 80,000 derivative securities directly.

Sentiment

Score: 7

Explanation: The document reports a standard equity compensation event for a director, which is generally viewed positively as it aligns management interests with shareholders. It does not, however, provide direct insights into operational performance or significant strategic shifts.

Positives

• The grant of stock options to Director Hans Edgar Bishop aligns his financial interests directly with the long-term performance and shareholder value of Sana Biotechnology, Inc.
• Equity compensation is a standard practice that incentivizes directors to contribute to the company's growth and success.

Future Outlook

The document primarily details a compensation event and does not provide a forward-looking statement on the company's operational or financial performance, beyond the vesting schedule of the granted options.

Management Comments

• The stock option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 5, 2026 and (ii) immediately prior to the 2026 annual meeting of stockholders of Sana Biotechnology, Inc., provided that the reporting person provides continuous service to Sana through such date.

Industry Context

The grant of stock options to directors is a common and widely accepted practice in the biotechnology and broader corporate sectors, serving as a key component of executive and board compensation packages designed to align leadership incentives with long-term shareholder value creation.

Comparison to Industry Standards

• The granting of stock options to directors is a standard compensation practice across publicly traded companies, particularly prevalent in growth-oriented sectors like biotechnology, where long-term incentives are crucial.
• While the specific number of options (80,000) and exercise price ($2.55) are specific to Sana Biotechnology, the mechanism of equity-based compensation for board members is consistent with industry benchmarks for attracting and retaining qualified leadership.

Corporate Governance

Related Party Transactions

• The grant of stock options to a director, Hans Edgar Bishop, constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant of options to a director is intended to align the director's interests with those of shareholders, potentially leading to decisions that enhance long-term shareholder value.
• Employees: While not directly impacting general employees, such compensation practices for leadership can influence overall company culture and compensation philosophy.

Next Steps

• The stock options are scheduled to vest on the earlier of June 5, 2026, or immediately prior to the 2026 annual meeting of stockholders, contingent on Hans Edgar Bishop's continuous service to Sana Biotechnology, Inc.

Key Dates

Keywords

Sana Biotechnology, SANA, Stock Options, Director Compensation, SEC Form 4, Beneficial Ownership, Equity Grant, Biotechnology